The DOI matches its Crossref record.
Long-Term, Non-Nightly Administration of Zolpidem in the Treatment of Patients With Primary Insomnia
Abstract
Introduction While it is common practice that hypnotics are used on a non-nightly basis, few investigations have been undertaken to evaluate the efficacy of the intermittent dosing strategy. The present study was designed to further evaluate this issue within a large scale, double-blind, placebo-controlled, long-term trial. Method Patients who met DSM-IV criteria for primary insomnia participated in the study from January 2000 through October 2001. Patients were randomly assigned to 1 of 2 treatment groups (zolpidem 10 mg or placebo) for a period of 12 weeks. Ten pills were provided in foil packs on an every-other-week basis, and patients were instructed to take no fewer than 3 and no more than 5 pills per week. Sleep was evaluated daily with sleep diaries. Pill use was recorded in the sleep diaries. Results 199 patients (mean +/- SD age = 41.0 +/- 12.8 years; 71% female) were randomly assigned to treatment. On mean, patients receiving zolpidem exhibited (vs. baseline) a 42% decrease in sleep latency, a 52% reduction in number of awakenings, a 55% decrease in wake time after sleep onset, and a 27% increase in total sleep time. These positive clinical gains did not diminish with time and were not associated with dose escalation. There was also no evidence of rebound insomnia. Conclusions Over a period of 12 weeks of intermittent treatment with zolpidem, sleep continuity was significantly improved, the clinical gains were sustained, and there was no evidence of subjective rebou…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“empirical data support both nightly and intermittent (2-5 times per week) administration. 4951”
From Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults (2008) · cites this paper as [49]
Citations
Cited by
Sorted by citations
European guideline for the diagnosis and treatment of insomnia
Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., Espie, C. A., Garcia‐Borreguero, D., Gjerstad, M., Gonçalves, M., et al. (2017) · Journal of Sleep Research · doi:10.1111/jsr.12594 · Cited by 2,049
Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2016) · Annals of Internal Medicine · doi:10.7326/m15-2175 · Cited by 1,965
Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults
Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., & Sateia, M. (2008) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27286 · Cited by 1,943
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
“57,72,75,76,78,82 The mean difference fell below the level of clinical significance at −13.57 min (CI: −7.30 to −19.84 min).”
InfluentialSelf-citationMorin, C., Vallières, A., Guay, B., Ivers, H., Savard, J., Mérette, C., Bastien, C., & Baillargeon, L. (2009) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2009.682 · Cited by 766
Harrison, T., & Keating, G. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00008 · Cited by 303
S3-Leitlinie Nicht erholsamer Schlaf/Schlafstörungen
Riemann, D. W., Baum, E., Cohrs, S., Crönlein, T., Hajak, G., Hertenstein, E., Klose, P., Langhorst, J., Mayer, G., Nissen, C., et al. (2017) · Somnologie - Schlafforschung und Schlafmedizin · doi:10.1007/s11818-016-0097-x · Cited by 354
Sleep Disturbance in Bipolar Disorder: Therapeutic Implications
Plante, D. T., & Winkelman, J. W. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08010077 · Cited by 268
“Although BzRAs also have potential for tolerance and withdrawal, there is evidence that non-nightly use of BzRAs over 8–12 weeks is not associated with such sequelae (131, 132).”
BackgroundThe assessment and management of insomnia: an update
Krystal, A. D., Prather, A. A., & Ashbrook, L. H. (2019) · World Psychiatry · doi:10.1002/wps.20674 · Cited by 256
Self-citationWilt, T., MacDonald, R., Brasure, M., Olson, C. M., Carlyle, M., Fuchs, E., Khawaja, I., Diem, S., Koffel, E., Ouellette, J., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1781 · Cited by 229
Krystal, A., Erman, M., Zammit, G., Soubrane, C., & Roth, T. (2008) · Sleep · doi:10.1093/sleep/31.1.79 · Cited by 201
Self-citationGooneratne, N. S., & Vitiello, M. V. (2014) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2014.04.007 · Cited by 206
Treating insomnia: Current and investigational pharmacological approaches
Ebert, B., Wafford, K. A., & Deacon, S. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.04.014 · Cited by 169
Searching for perfect sleep: the continuing evolution of GABA A receptor modulators as hypnotics
Nutt, D. J., & Stahl, S. M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106927 · Cited by 163
“Zolpidem IR improves sleep latency and has shown inconsistent effects on sleep maintenance (Scharf et al., 1994; Monti et al., 1996; Walsh et al., 2000b; Perlis et al., 2004) (Table 6).”
BackgroundKärppä, M., Yardley, J., Pinner, K., Filippov, G., Zammit, G., Moline, M., Perdomo, C., Inoue, Y., Ishikawa, K., & Kubota, N. (2020) · Sleep · doi:10.1093/sleep/zsaa123 · Cited by 161
Krystal, A. D. (2009) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2008.08.001 · Cited by 180
Self-citationManagement of chronic insomnia in elderly persons
Bain, K. T. (2006) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2006.06.006 · Cited by 119
Silber, M. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp043762 · Cited by 136
Hanlon, J. T., Semla, T. P., & Schmader, K. E. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13807 · Cited by 130
Comparative Tolerability of Newer Agents for Insomnia
Zammit, G. (2009) · Drug Safety · doi:10.2165/11312920-000000000-00000 · Cited by 98
Reviews: Diagnosis and Management of Insomnia in Dialysis Patients
Novak, M., Shapiro, C., Mendelssohn, D., & Mucsi, I. (2006) · Seminars in dialysis · doi:10.1111/j.1525-139x.2006.00116.x · Cited by 97
“However, recent data support the feasibility of long-term pharmacologic management of chronic insomnia without evidence of tolerance or abuse (57,58).”
BackgroundHypnotics in Insomnia: The Experience of Zolpidem
MacFarlane, J., Morin, C. M., & Montplaisir, J. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.09.017 · Cited by 94
Tackling sleeplessness: psychological treatment options for insomnia in older adults
McCrae, C. (2010) · Nature and Science of Sleep · doi:10.2147/nss.s7064 · Cited by 40
Yardley, J., Kärppä, M., Inoue, Y., Pinner, K., Perdomo, C., Ishikawa, K., Filippov, G., Kubota, N., & Moline, M. (2021) · Sleep Medicine · doi:10.1016/j.sleep.2021.01.048 · Cited by 80
Role of Zolpidem in the Management of Insomnia
Dang, A., Garg, A., & Rataboli, P. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00158.x · Cited by 80
“Number of studies suggest that zolpidem in the dose of 5 to 10 mg is safe even for longer treatment periods of up to 35 days to 3 months of treatment [62,63].”
BackgroundPlacebo effects in primary insomnia
Perlis, M. L., McCall, W. V., Jungquist, C. R., Pigeon, W. R., & Matteson, S. E. (2005) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2005.05.001 · Cited by 75
Self-citationEfficacy and safety of zolpidem extended release in elderly primary insomnia patients.
Walsh, J., Soubrane, C., & Roth, T. (2008) · The American journal of geriatric psychiatry · doi:10.1097/jgp.0b013e3181256b01 · Cited by 75
Self-citationMonti, J. M., Spence, D. W., Buttoo, K., & Pandi-Perumal, S. R. (2016) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2016.10.006 · Cited by 85
Morin, C. M., Beaulieu‐Bonneau, S., Ivers, H., Vallières, A., Guay, B., Savard, J., & Mérette, C. (2014) · Sleep Medicine · doi:10.1016/j.sleep.2014.02.004 · Cited by 55
“[33]), thus questioning the need to add a more demanding behavioral intervention.”
BackgroundTreatment of sleep dysfunction and psychiatric disorders
Becker, P. M., & Sattar, M. T. (2009) · Current Treatment Options in Neurology · doi:10.1007/s11940-009-0039-z · Cited by 53
New guidelines for diagnosis and treatment of insomnia
Pinto, L. R., Alves, R. C., Caixeta, E. C., Fontenelle, J. A., Bacellar, A., Poyares, D. R., Alóe, F., Rizzo, G. N. V., Minhoto, G. R., Bittencourt, L., et al. (2010) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2010000400038 · Cited by 52
Perlis, M., Grandner, M., Zee, J., Bremer, E., Whinnery, J., Barilla, H., Andalia, P. A., Gehrman, P., Morales, K., Thase, M., et al. (2015) · Sleep Medicine · doi:10.1016/j.sleep.2015.06.015 · Cited by 40
“What is clear from the given data is that there are no treatment effects on non-medication nights [11].”
BackgroundSelf-citationScharf, M. B., Black, J. E., Hull, S. G., Landin, R., & Farber, R. (2007) · SLEEP · doi:10.1093/sleep/30.6.743 · Cited by 38
Pan, B., Ge, L., Lai, H., Hou, L., Tian, C., Wang, Q., Yang, K., Lü, Y., Zhu, H., Li, M., et al. (2023) · Drugs · doi:10.1007/s40265-023-01859-8 · Cited by 44
Pharmacologic management of insomnia: past, present, and future.
Curry, D. T., Eisenstein, R. D., & Walsh, J. (2006) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.09.006 · Cited by 38
Self-citationPharmacologic and Nonpharmacologic Treatments of Insomnia
Becker, P. M. (2005) · Neurologic Clinics · doi:10.1016/j.ncl.2005.05.002 · Cited by 32
Non-Benzodiazepine Receptor Agonists for Insomnia.
Becker, P., & Somiah, M. (2015) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2014.11.002 · Cited by 32
Chapter 81 – Pharmacologic Treatment of Insomnia: Benzodiazepine Receptor Agonists
Walsh, J., & Roth, T. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6645-3.00081-5 · Cited by 26
Self-citationMcCall, W., Kimball, J., Boggs, N., Lasater, B., D'Agostino, R., & Rosenquist, P. (2009) · Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · doi:10.5664/jcsm.27602 · Cited by 26
Self-citationPharmacologic Treatment of Primary Insomnia
Hall-Porter, J. M., Curry, D. T., & Walsh, J. K. (2010) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2010.08.006 · Cited by 31
Self-citationPolysomnographic Study of Intermittent Zolpidem Treatment in Primary Sleep Maintenance Insomnia
Parrino, L., Smerieri, A., Giglia, F., Milioli, G., de Paolis, F., & Terzano, M. (2008) · Clinical neuropharmacology · doi:10.1097/wnf.0b013e3180674e0e · Cited by 24
“During the intermittent treatment with zolpidem, sleep continuity improved significantly, these clinical gains were sustained, and there was no evidence of subjective rebound insomnia between doses or increase in the amount of medication used during the study interval.(20)”
BackgroundRoth, T., Zammit, G., Scharf, M., & Farber, R. (2007) · Sleep · doi:10.1093/sleep/30.12.1731 · Cited by 23
Overview of currently available benzodiazepine and nonbenzodiazepine hypnotics
Monti, J. M., & Monti, D. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7440-3_14 · Cited by 24
Insomnia in Patients with Depression
Jindal, R. D. (2009) · CNS Drugs · doi:10.2165/00023210-200923040-00004 · Cited by 33
Long-term, Non-nightly Administration of Zolpidem in the Treatment of Patients With Primary Insomnia
Ballenger, J. (2006) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70258-5 · Cited by 21
The Diagnosis and Treatment of Insomnia
Skalski, M. (2012) · InTech eBooks · doi:10.5772/31056 · Cited by 20
Poyares, D., Pinto, L. R., Tavares, S., & Barros-Vieira, S. (2005) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462005000500002 · Cited by 20
What is “evidence” in psychotherapies?
Lilienfeld, S. (2019) · World Psychiatry · doi:10.1002/wps.20654 · Cited by 18
Yu, D. J., Recchia, F., Bernal, J. D. K., Yu, A. P., Fong, D., Li, S. X., Chan, N. Y., Hu, X., & Parco Ming-fai, S. I. U. (2023) · Healthcare · doi:10.3390/healthcare11152207 · Cited by 21
Intermittent and long-term use of sedative hypnotics.
Perlis, M., Gehrman, P., & Riemann, D. (2008) · Current pharmaceutical design · doi:10.2174/138161208786549290 · Cited by 16
“Perlis et al. 2004 [33].”
BackgroundSelf-citationMorin, C. M., & Benca, R. M. (2010) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52007-4.00004-7 · Cited by 22
Can't Sleep? Issues of Being an Insomniac
Sahoo, S. (2012) · doi:10.5772/1220 · Cited by 15
Age-Related Effects on Circadian Phase in the Sleep of Patients with Depression and Insomnia
Xian, H., Gonzalez, C., Deych, E., Farris, S., Ding, J.-M., Shannon, W., & McCall, W. (2015) · Behavioural Sleep Medicine · doi:10.1080/15402002.2013.855213 · Cited by 14
Self-citationPharmacologic Management of Chronic Insomnia
Taylor, J. R., Vázquez, C., & Campbell, K. M. (2006) · Southern medical journal (Birmingham, Ala. Print) · doi:10.1097/01.smj.0000243131.25116.bd · Cited by 14
Lichstein, K. (2006) · Sleep Medicine · doi:10.1016/j.sleep.2006.03.004 · Cited by 14
“Although hypnotic dependence is clearly a problem, the limited data currently available do not indicate development of tolerance to the newer non-benzodiazepines [4,5].”
BackgroundClinical Pharmacology of Sleep
Pandi-Perumal, S. R., & Monti, J. M. (2006) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7440-3 · Cited by 31
Song, Y., & Ku, J. (2007) · International Urology and Nephrology · doi:10.1007/s11255-007-9206-x · Cited by 13
New paradigms in the pharmacological treatment of insomnia
Hajak, G. (2006) · Sleep Medicine · doi:10.1016/j.sleep.2006.03.003 · Cited by 13
Pharmacologic Treatment of Primary Insomnia
Walsh, J. K., Roehrs, T., & Roth, T. G. (2005) · Elsevier eBooks · doi:10.1016/b0-72-160797-7/50070-7 · Cited by 52
Self-citationSleep Disorders in Women Veterans
Martin, J. L., Badr, M. S., & Zeineddine, S. (2018) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2018.04.010 · Cited by 11
Wisłowska-Stanek, A., Jarkiewicz, M., & Mirowska-Guzel, D. M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00689-z · Cited by 11
“Other symptoms are nausea, nightmares, and insomnia [9, 55 ].”
Silber, M. H. (2007) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000275606.54292.cc · Cited by 1
“Intermittent use of zolpidem (3 to 5 times a week) has been shown to produce sustained benefit on nights the drug is taken, with no worse than baseline insomnia on other nights (Perlis et al, 2004) (Case 3-1).”
Chronic insomnia: current issues
Neubauer, D. N. (2004) · Clinical cornerstone · doi:10.1016/s1098-3597(04)80044-9 · Cited by 9
Stapel, B., Alvarenga, M. E., & Kahl, K. G. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1490585 · Cited by 8
Lohse, M., & Müller-Oerlinghausen, B. (2020) · Arzneiverordnungs-Report 2020 · doi:10.1007/978-3-540-69219-5_28 · Cited by 8
Sleep and Its Modulation by Substances That Affect GABAA Receptor Function
Steiger, A. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0226-6_5 · Cited by 9
“The efficacy of a dose of 10 mg zolpidem taken intermittently (3–4 nights weekly) persisted during 3 months as indicated by improved sleep latency, nocturnal awakenings, and total sleep time [34].”
BackgroundEfficacy of Hypnotic Medications and Other Medications Used for Insomnia
Feren, S. D., Katyal, A., & Walsh, J. (2006) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2006.06.011 · Cited by 7
Self-citationNew Approaches in Managing Chronic Insomnia
Neubauer, D. (2006) · CNS Spectrums · doi:10.1017/s1092852900026687 · Cited by 7
Chapter 87 – Pharmacologic Treatment of Insomnia: Benzodiazepine Receptor Agonists
Walsh, J., & Roth, T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-24288-2.00087-8 · Cited by 7
Self-citationSonolência excessiva diurna e depressão: causas, implicações clínicas e manejo terapêutico
Chellappa, S. L. (2009) · Revista de Psiquiatria do Rio Grande do Sul · doi:10.1590/s0101-81082009000400001 · Cited by 6
Hypnotic Medications as an Adjunct Treatment to Cognitive Behavioral Therapy for Insomnia
Barkopoulos, P., & Cho, H. J. (2023) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2022.10.004 · Cited by 7
Monti, J., Pandi-Perumal, S. R., & Möhler, H. (2010) · doi:10.1007/978-3-0346-0226-6 · Cited by 5
“The most important study in relation to the human thalamus has been the mapping of the mRNA distribution of ten GABAAR subunits, which was carried out in a series of sections through the monkey thalamus [34].”
BackgroundNeubauer, D., & Flaherty, K. N. (2009) · Seminars in neurology · doi:10.1055/s-0029-1237125 · Cited by 4
Insomnia: recent developments in definition and treatment
Atalay, H. (2006) · Primary Care and Community Psychiatry · doi:10.1185/135525706x121138 · Cited by 4
Abhängigkeitspotenzial der GABA-A-Rezeptor-agonistischen Nicht-Benzodiazepin-Hypnotika
Lange, K., Wodarz, N., & Hajak, G. (2007) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/2007.04.02 · Cited by 4
Feren, S. D., Schweitzer, P., & Walsh, J. (2011) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52007-4.00005-9 · Cited by 3
Self-citationZolpidem in the Treatment of Adult and Elderly Primary Insomnia Patients
Staner, L., Cornette, F., Otmani, S., Nedelec, J. F., & Danjou, P. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0226-6_17 · Cited by 3
“Studies on the intermittent use of zolpidem also indicate a low [91], if any [92, 140], potential for rebound insomnia.”
BackgroundInfluential22 – Patients with Disordered Sleep
Smallwood, P., Quinn, D. K., & Stern, T. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-1927-7.00022-4 · Cited by 3
Pharmacological Treatment of Insomnia
Schweitzer, P. K., Curry, D. T., Eisenstein, R. D., & Walsh, J. K. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-042-7_23 · Cited by 9
Self-citationKrystal, A. D., Benca, R. M., McCall, W. V., Perlis, M. L., Watson, N. F., Winkelman, J. W., Fisher, M., & Morin, C. M. (2026) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2026.102246 · Cited by 1
Self-citationThe long-term use of sedative hypnotics in chronic insomnia
Heesch, C. B. (2014) · Mental Health Clinician · doi:10.9740/mhc.n190097 · Cited by 2
Role of zolpidem in the management of primary and comorbid insomnia
Monti, J., & Pandi-Perumal, S. R. (2014) · doi:10.2217/fmeb2013.13.146 · Cited by 2
Doo, S., Kim, J. H., Yang, W., & Song, Y. (2013) · Lower urinary tract symptoms · doi:10.1111/luts.12001 · Cited by 2
Nature and Treatment of Insomnia
Morin, C. M., Savard, J., & Ouellet, M. (2012) · Wiley eBooks · doi:10.1002/9781118133880.hop209014 · Cited by 4
Benzodiazepine Receptor Agonists: Indications, Efficacy, and Outcome
Krystal, A. D. (2010) · Medical psychiatry · doi:10.3109/9781420080803.032 · Cited by 1
Self-citationNature, Evaluation, and Treatment of Insomnia
Morin, C. M., & Benca, R. M. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6578-6_37 · Cited by 4
Pharmacology of Benzodiazepine Receptor Agonist Hypnotics
Roehrs, T., Diederichs, C., & Roth, T. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1703-7.10007-6 · Cited by 2
Clinical Medicine Insights: Geriatrics
Sakuraba, A. (2018) · Clinical Medicine Insights Geriatrics · doi:10.4137/cmger · Cited by 5
Role of Sleep Aids and Wake-Promoting Agents During Cognitive Behavior Therapy for Insomnia
Das, S., & Gupta, R. (2017) · Current Sleep Medicine Reports · doi:10.1007/s40675-017-0095-y · Cited by 1
Z-drugs: comparative tolerability
Terzano, M., Milioli, G., de Paolis, F., & Parrino, L. (2008) · doi:10.3109/9780203091715-35 · Cited by 1
Monti, J. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6578-6_55 · Cited by 1
Wright, B. T. (2016) · doi:10.21007/etd.cghs.2016.0408 · Cited by 1
“The studies also found there were no withdrawal effects such as next day insomnia or cognitive dysfunction [27, 40].”
Pharmacological Treatment of Insomnia
Parish, J. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-421-6_5 · Cited by 1
Primary insomnia: diagnosis and treatment
Sakkas, P., & Soldatos, C. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7440-3_2 · Cited by 1
Pharmacologic Treatment of Insomnia
Neubauer, D. N. (2008) · Wiley eBooks · doi:10.1002/9780470515167.ch105 · Cited by 1
Self-citationPharmacologic Treatment of Insomnia
Neubauer, D. N., Minkel, J. D., & Krystal, A. D. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch107
Self-citationAdvances in the Management of Primary and Secondary Insomnia
McCall, W. V. (2014) · doi:10.2217/9781780844800 · Cited by 2
Self-citationЛисицына, Т. А., Seravina, O., & Veltishchev, D. (2010) · RSP · doi:10.14412/1995-4484-2010-735
Clinical Trials and the Development of New Therapeutics for Insomnia
Zammit, G. K. (2010) · Medical psychiatry · doi:10.3109/9781420080803.038
Pharmacologic treatment of insomnia
Harris, S., Thorpy, M., & Monderer, R. (2021) · Reference Module in Neuroscience and Biobehavioral Psychology · doi:10.1016/b978-0-12-822963-7.00101-8
Metadata
- Authors
- Perlis, M. L., McCall, W. V., Krystal, A. D., & Walsh, J. K.
- Affiliations
- University of Rochester Medicine (US)
- Wake Forest University (US)
- Duke University (US)
- Saint Louis University (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2004-08-15
- Volume
- 65
- Issue
- 8
- Pages
- 1128-1137
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1995438590
- Cited by
- 144
- References
- 0
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 6 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 10 · 2016: 8 · 2015: 4 · 2014: 10 · 2013: 2 · 2012: 5
- FWCI
- 18.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and Work-Related Fatigue
- Keywords
- zolpidem, primary insomnia, intermittent dosing, hypnotics, long-term treatment, sleep latency, awakening, wake after sleep onset, total sleep time, rebound insomnia, dose escalation, sleep continuity
- MeSH terms
- Zolpidem, Adolescent, Adult, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Hypnotics and Sedatives, Sleep Initiation and Maintenance Disorders, Longitudinal Studies, Male, Medical Records, Middle Aged, Placebos, Pyridines, Surveys and Questionnaires, Sleep, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
